October 2026 numbers from each country's official database — and why the gap shrank since 2016 but didn't close.
Researched with AI assistance; every figure is checked against the primary source cited on this page before publishing. How we work →
Price for two doses of epinephrine, from each country's official source, converted to US dollars at European Central Bank reference rates of October 20, 2026. US figures are what pharmacies pay (CMS NADAC), not what an insured patient pays at the counter. The European figures are each system's official price level — retail prices including VAT in Germany and Switzerland, the social-insurance price excluding VAT in Austria, the average pharmacy price in the Netherlands — so they are not exactly like-for-like with the US acquisition cost.
| Country | Price for 2 doses | In US dollars | What a patient typically pays |
|---|---|---|---|
| 🇺🇸 United States (generic) | $224.75 pharmacy cost | $225 | Depends on insurance; a few states cap it |
| 🇺🇸 United States (Auvi-Q / neffy) | $618.75 / $719.14 pharmacy cost | $619 / $719 | Depends on insurance |
| 🇬🇧 United Kingdom | £121.38 NHS price | $162 | £9.90 in England; free in Scotland, Wales, Northern Ireland |
| 🇫🇷 France | €91.32 official price | $102 | 35% (about €32) unless a complementary insurer covers it |
| 🇦🇺 Australia | PBS-subsidised | — | A$25 (about $17); A$7.70 with a concession card |
| 🇩🇪 Germany | €147.12 statutory ceiling (Festbetrag) | $165 | €10 co-payment (10%, min. €5, max. €10); more if a product is priced above the ceiling |
| 🇨🇭 Switzerland | CHF 109.30 official public price | $133 | Adults: first CHF 300 a year in full, then 10% up to CHF 700 a year |
| 🇦🇹 Austria | €121.10 (2 × €60.55, excl. VAT) | $136 | €7.55 prescription fee per pen — €15.10 for two |
| 🇳🇱 Netherlands | €96.94 (2 × €48.47) | $109 | Reimbursed, but counts against the compulsory deductible (up to €385 in 2026) |
| Market | Figure | Context | Source |
|---|---|---|---|
| United States — generic | $224.75 / 2 pens (pharmacy cost) | CMS's NADAC survey puts the generic epinephrine 0.3 mg auto-injector at $112.37 per pen as of October 21, 2026 — about $225 for the usual two-pack. That is what pharmacies pay, not a shelf price: what a patient pays depends on insurance, and only a handful of states cap it. | CMS NADAC (Oct 21, 2026) |
| The catch — US brand & needle-free | $618.75 Auvi-Q · $719.14 neffy (per 2) | Brand-name options still sit far higher in the same NADAC data: Auvi-Q at $309.38 per injector and the needle-free nasal spray neffy at $359.57 per device. The brand EpiPen 0.3 mg pen itself no longer appears in the 2026 NADAC survey. | CMS NADAC (Oct 21, 2026) |
| France | €91.32 / 2 pens (≈ $102) | France's public medicines database lists a box of two EpiPen 0.30 mg pens at €91.32 (€92.34 with the dispensing fee). Social Security reimburses 65%; the remaining 35% — about €32 — falls to the patient or their complementary insurer (mutuelle). | BDPM / ANSM (retrieved Oct 21, 2026) |
| United Kingdom | £121.38 / 2 pens (≈ $162) | The NHS indicative price for an EpiPen 300 microgram two-pack has been £121.38 since July 1, 2024. Patients don't pay it: in England it's the standard £9.90 prescription charge for 2026/27 (about 89% of prescriptions are dispensed free), and prescriptions are free in Scotland, Wales and Northern Ireland. | NHSBSA dm+d · DHSC 2026/27 charges |
| Australia | A$25 patient co-payment (≈ $17) | On the PBS, a general patient pays at most A$25.00 per prescription from January 1, 2026 (down from A$31.60), and concession-card holders A$7.70. The government covers the rest of the price. | PBS / Department of Health (2026) |
| History — the 2016 peak | $608.61 / 2-pack (2016 brand list) | The number that made EpiPen a symbol: the brand list price climbed from under $100 (2007) to $608.61 by 2016 and put Mylan's CEO before Congress. Today's generic costs US pharmacies roughly a third of that. | US congressional record (2016) |
We compare what the auto-injector costs, not what anyone should take, switch, or stop. Nothing here endorses relying on an expired device. Epinephrine decisions belong with you, your pharmacist, and a licensed prescriber.
The headline number of the EpiPen story belongs to 2016, when the brand two-pack listed at $608.61. Generics changed that: in October 2026 the generic auto-injector costs US pharmacies about $225 for two, and the brand EpiPen 0.3 mg pen has dropped out of the national pharmacy-cost survey. What hasn't changed is the structure. France still pays one negotiated national price of €91.32; the NHS pays £121.38 and charges patients £9.90 or nothing. The US generic remains about twice France's price, and the brand and needle-free options remain six to seven times higher.
Industry pharmacists estimate the epinephrine inside costs well under a dollar, with the auto-injector device adding a few dollars more. That is an honest estimate, not an audited accounting figure — but the direction is clear enough that a JAMA Network Open analysis could estimate the value-based ceiling for a twin-pack at roughly $24–$35. Measured against a ~$715 market price, the same analysis put the cost at about $2.7 million per quality-adjusted life year. The gap between what the device is worth and what it's priced at is the whole story.
Relief came in pieces. Mylan's authorized generic launched at $300 in December 2016; the FDA cleared a truly substitutable generic (Teva) in August 2018; branded share collapsed from about 95% of prescriptions in 2015 to a reported 11% by 2019. But the newest option undercuts the "innovation lowers prices" reflex: neffy, the needle-free nasal spray approved in August 2024, launched at a $710 wholesale price for two doses and still costs pharmacies about $719 for two devices in October 2026. Before paying list, the practical moves are knowing the authorized generic exists, checking whether your state caps patient cost (only a handful do, and there is no federal cap), and asking the pharmacist about automatic substitution at the counter.
As of October 2026, a generic epinephrine auto-injector two-pack costs US pharmacies about $225 (CMS NADAC: $112.37 per pen). France's official price for two EpiPen 0.30 mg pens is €91.32, about $102 (BDPM). The NHS price for a two-pack is £121.38, about $162 (NHSBSA). Brand-name and needle-free options stay higher in the US: about $619 for two Auvi-Q injectors and $719 for two neffy sprays at pharmacy cost.
France lists a box of two EpiPen 0.30 mg pens at €91.32 (€92.34 with the dispensing fee), with 65% reimbursed by Social Security. In the UK the NHS price is £121.38 per two-pack, but patients in England pay the standard £9.90 prescription charge — and nothing in Scotland, Wales or Northern Ireland. Prices are October 2026 figures from each country's official database.
Not manufacturing. Industry pharmacists estimate the epinephrine itself costs well under a dollar and the device a few dollars more. The 2007-to-2016 climb from under $100 to $608.61 tracked pricing decisions, not chemistry — Mylan's CEO, Heather Bresch, was called before Congress in September 2016 to explain it, and the company later paid a $465 million settlement to the Department of Justice over Medicaid classification (2017).
A JAMA Network Open analysis estimated the value-based ceiling for an epinephrine twin-pack at roughly $24–$35, assuming it cuts fatality risk tenfold. At the ~$715 market price the researchers used instead, the cost worked out to about $2.7 million per quality-adjusted life year — a gap between what the device is worth and what it's priced at.
Slowly. Mylan launched its own authorized generic at $300 that December, but the FDA didn't approve a true, automatically substitutable generic until August 2018 (Teva). Branded share fell from about 95% of prescriptions (2015) to a reported 11% (2019), and average out-of-pocket spending dropped from about $116 to $76 (2019) — though roughly 1 in 13 privately insured patients still paid over $200.
The generic epinephrine auto-injector is the cheaper option in the US — about $225 per two-pack at pharmacy cost in October 2026. The needle-free nasal spray neffy, FDA-approved in August 2024, is not cheaper: it launched at $710 for two doses and sits at about $719 for two devices in the October 2026 NADAC data. Needle-free is a convenience difference, not a price difference.
Know the authorized generic exists, check your state's cap (Colorado and Illinois reportedly cap patient cost near $60 a two-pack; New Jersey at $25 per 30-day supply — only a handful of states, with no federal limit), and ask your pharmacist about automatic substitution before the counter. A cheaper Adrenaclick-style version uses a different device and generally can't be swapped automatically. This is cost information, not medical advice — never rely on an expired auto-injector, and epinephrine decisions belong with a licensed prescriber.
Wellness Vision does not sell medication, book trips, or take referrals. Every figure above traces to the public sources cited — a congressional hearing record, a government medicines database, a peer-reviewed journal, a regulator, and a company filing. This is a cost comparison, not medical advice: nothing here tells anyone to start, stop, switch, or rely on an expired auto-injector, and an epinephrine device is emergency equipment where the right call is always a licensed prescriber's.
📋 Or get the free Medical Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
